Articles

Abbott began enrolling U.S. patients in the EXCEL trial, which will compare the use of the Xience Prime or Xience V drug-eluting strents to coronary artery bypass graft (CABG) surgery for...

There have been several key news items from the U.S. stent market over the past year. These include the introduction of several new stents, Cordis pulling out of the market, an expanded indication...

New developments in drug-eluting stents, such as biodegradable materials and bifurcated stents, are expected to prompt an increase in market value. Companies like Biosensors and Abbott are...

September 8, 2011 – Patients at a high risk for a second stroke who received intensive medical treatment had fewer strokes and deaths than patients who received a brain stent in addition to the...

A drug-eluting, self-expanding stent that does not use a drug-carrier polymer is before the U.S. Food and Drug Administration (FDA) final pre-market approval (PMA) review and a decision is...

Navigating through the world of coronary stents is about to become more complex.  A plethora of new products are on the horizon, which will utilize new platforms and alloys and present novel...

Carotid stenting is a more complex and challenging procedure than coronaries or peripheral vessels. Carotid stenting experts have the following advice for hospitals and physicians that want to...

In a move that will likely have a significant impact on how many patients are treated for carotid artery disease, the U.S. Food and Drug Administration (FDA) in May cleared the use of a stent to...

In a move that will likely have a significant impact how many patients are treated for carotid artery disease, the U.S. Food and Drug Administration (FDA) has cleared the use of a stent to treat...

April 9, 2011 - The Resolute zotarolimus-eluting stent using a new biocompatible polymer achieved a lower rate of restenosis and in-stent thrombosis compared to the Endeavor stent at 12 months in...